Eremid Genomic Services — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Eremid Genomic Services is a specialized genomics CRO founded in 2014 and headquartered in Charlottesville, Virginia. It operates a dual model, offering both research-grade and CLIA/CAP-accredited clinical genomics services across three key sectors: agricultural biotechnology, food & nutrition, and human health (with a focus on cancer and immuno-oncology). The company differentiates itself through a consultative, full-service approach, combining cutting-edge sequencing and bioinformatics technologies with expert project management to accelerate client research from concept to data.

OncologyOther Human Health

Technology Platform

Integrated suite of advanced genomics and bioinformatics services utilizing cutting-edge long-read sequencing (e.g., PacBio Revio), microarray scanners, and CLIA/CAP-accredited labs for end-to-end project support from design to data interpretation.

Opportunities

The growing demand for outsourced, complex genomic analysis in research and clinical settings across AgBiotech, Food & Nutrition, and Human Health presents a significant expansion opportunity.

Its CLIA/CAP accreditation allows it to capture premium revenue from the regulated clinical genomics market.

Strategic partnerships with technology providers or large industry players could accelerate growth and market penetration.

Risk Factors

Intense competition from larger CROs and specialized labs threatens market share and pricing power.

Rapid technological obsolescence requires continuous capital investment.

The service-based model offers limited proprietary IP, making the business highly reliant on reputation and client relationships, which can be volatile.

Competitive Landscape

Eremid competes in a crowded genomics services market against large, diversified CROs (e.g., LabCorp, Charles River), diagnostic service labs, and academic core facilities. Its differentiation lies in its combined research/clinical accreditation, tri-sector focus, and highly customized, consultative service model. However, it faces pressure from low-cost providers and must continually demonstrate superior scientific expertise and project management to justify its value proposition.

More companies in Diagnostics & Precision Medicine →More companies in United States →